T cells in their abnormal interface with B cells cause tissue damage, and auto-antigen release, leading to further activation and differentiation of self-reactive CD4+ T cells. Recognition of MHC/Self-peptide plays a causative role in autoimmunity 1,2. How this leads to abnormal activation of CD4+ T cells is not clear.

Methods We optimized a single cell resolution method – bar-coded phosphoflow 3- to quantitatively measure intracellular signaling pathways in T cells that encounter MHC/Self-peptide. We unleashed this method on T cells from various genetic mouse models and combined this with a novel methodology to measure cell metabolism, SCENITH, also with single cell resolution.

Results RasGRP1 has been associated with autoimmune diseases, but the genetic basis or impact on T cells is not known. Likewise, mTORC1 signals and altered cell metabolism links to autoimmunity and the mTOR inhibitor Rapamycin reduces disease severity in autoimmune patients and mouse models. In our studies, we uncovered a novel Rasgrp1-mTORC1 pathway that is selectively triggered when T cells see MHC/Self-peptide (see figure 1). In our Rasgrp1Anaef mouse model 4,5 a single R519G point mutation results in aberrantly elevated Rasgrp1Anaef-mTORC1 signals that drive resting T cells out of their naïve state, leading to autoimmune pathology 4. Mechanistically, this elevated Rasgrp1Anaef-mTORC1 signal does not lead to altered gene expression, but instead, results in unwanted translation of mRNA targets in naïve T cells 4.

Conclusions Thus, Rasgrp1-mTORC1 signals are selectively triggered when T cells see self and are highest when T cells see self the strongest (auto-reactive) 4. We are investigating the fundamental properties of Rasgrp1-mTORC1 signals and effects on metabolism and protein translation. We are complementing these directions with efforts on SLE and RA patient samples and desire to expand this area through Dr. Roose's roles in UCSF ImmunoX and AutoImmunoProfiler.

Abstract 603 Figure 1

REFERENCES

1. Myers DR, et al. *Immunol Rev.* 2019;291.
2. Myers DR, et al. *Trends Immunol.* 2017;38.
3. Kulhanek KR, et al. *STAR Protoc.* 2020;1.
4. Myers DR, et al. *Cell Reports.* 2019;27.
5. Daley SR, et al. *eLife.* 2013;2.

Acknowledgments We thank all members of the Roose lab for helpful discussions and the UCSF Parnassus Flow Cytometry Core for assistance with cell sorting (NIH P30 DK063720), the UCSF Genomics CoLab for RNA-Seq library preparation, the UCSF Center for Advanced Technology for sequencing, Max Horlbeck for assistance with bioinformatics. These studies were supported by grants from the NSF-GRFP (1650113 to DRM), the Marie Curie IOF (#PIOF-GA-2012-328666), and the NIH-NIAID (R01-AI104789 and P01-AI091580 to JPR).

700 – Macrophage in SLE

701

THERAPY OF DIFFUSE ALVEOLAR HEMORRHAGE IN EXPERIMENTAL LUPUS WITH RECOMBINANT MYXOMAVIRUS PROTEIN SERP-1

¹Haoyang Zhuang, ¹Shuhong Han, ²Li Lu, ^{1,2}Westley H Reeves*. ¹Division of Rheumatology, Allergy and Clinical Immunology; ²Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL USA

10.1136/lupus-2021-lupus21century.36

Background Although diffuse alveolar hemorrhage (DAH) is an uncommon complication of SLE, over half of patients die. B6 mice with pristane-induced lupus and DAH are an animal model of this disorder. ANCA-negative small vessel vasculitis with hemorrhage and hemosiderin-laden macrophages are seen in lung tissue from both SLE patients and mice with DAH. DAH in pristane-lupus is prevented by depleting macrophages whereas neutrophil depletion has no effect. IL-10 deficiency exacerbates DAH while macrophage repolarization induced by liver X receptors (LXR) prevents it. The myxomavirus-encoded serpin Serp-1 impairs macrophage activation and plasminogen activation and blocks DAH caused by MHV68 infection. We asked whether it also could block DAH in pristane-induced lupus.

Methods B6 mice were treated with pristane ± daily injection of recombinant Serp-1. Severity of DAH was assessed at day-14 by gross pathology, H&E, and Prussian blue staining. LXR activation was assessed by measuring *Nr1h3* mRNA (encoding LXRα) and flow cytometry for the LXR-regulated ATP Binding Cassette Subfamily A Member 1 (ABCA1) protein. The effect of Serp-1 on macrophage polarization was investigated in lung tissue and in RAW264.7 cells.

Results DAH was prevented by recombinant Serp-1. Serp-1 treatment repolarized macrophages toward an anti-inflammatory M2-like phenotype, increased expression of the transcription factor.

Kruppel-like factor-4 (*Klf4*), which regulates IL-10 production, and increased expression of *Nr1h3*, which along with *Klf4* regulates M2 polarization. Serp-1 also corrected a lupus-associated deficit of LXR-regulated reverse cholesterol transporter protein ABCA1. In RAW264.7 cells, Serp-1 increased *Klf4* mRNA levels and LPS-stimulated IL-10 secretion while reducing TNFα. Although Serp-1 affects both thrombotic and

thrombolytic pathways, the induction of DAH by pristane was unaffected by the absence of plasminogen activator inhibitor1 or tissue plasminogen activator, suggesting that protection is related to the action of Serp-1 on macrophage function.

Conclusions Serp-1 blocks pristane-induced lung hemorrhage by enhancing LXR-regulated M2 macrophage polarization and Klf4-regulated IL-10 production. In view of the similarities between DAH in pristane-treated mice and SLE patients, clinical trials of Serp-1 for DAH in SLE may be warranted. Since Serp-1 treatment increases expression of the reverse cholesterol transporter ABCA1, it also may have beneficial effects on atherosclerosis in SLE patients. Supporting the feasibility of future clinical studies in SLE, Serp-1 treatment reduced myocardial damage in patients with acute coronary syndrome.

Acknowledgments This work was supported by NIH grant R01-AR44731. We are grateful to Dr. Alexandra Lucas (Arizona State University) for providing recombinant Serp-1 protein.

702 PRISTANE INDUCED LUPUS IN HDAC6-MICE

Christopher M Reilly. *Edward Via College of Osteopathic Medicine, Blacksburg, Virginia, USA*

10.1136/lupus-2021-lupus21century.37

Background We and others have reported that selective histone deacetylase 6 (HDAC6) inhibition decreases inflammation in a variety of animal models including inflammatory arthritis and lupus. In this study, we explored whether HDAC6 gene deletion could affect pristane-induced lupus.

Methods C57BL/6 (w.t.) and HDAC6^{-/-} C57BL/6 mice were given 0.5 ml of pristane intraperitoneally (ip) at 3 months of age. Injection of pristane induces a lupus-like syndrome whose pathogenesis implicates the secretion of type I IFN by CD11b (+) Ly6C(high) inflammatory monocytes in a TLR7-dependent fashion. Two weeks after pristane administration the mice were euthanized and assessed for various parameters of inflammation. At termination of the experiment, serum, peritoneal macrophages, and splenic tissue was collected and evaluated.

Results The pristane treated animals euthanized showed diffuse alveolar hemorrhage, both w.t. and knock-outs. At sacrifice, spleens were significantly larger in the HDAC6^{-/-} mice compared to the w.t. pristane mice, however when compared to body weights there was not a significant difference. Flow cytometry did not indicate any differences in T cell or B cell populations. Sera IL-12, IL-6, TGF- β , IL-10, and TNF- α were comparable in the w.t. and the knock-out animals treated with pristane. Peritoneal recruitment of CD11b(+) Ly6C(high) inflammatory monocytes in HDAC6^{-/-} mice was significantly increased compared to the w.t. mice. Evaluation of the transcripts for several IFN inducible genes revealed significantly increased IRF-7 expression in the HDAC6^{-/-} mice however lower expression of IFN β and IRF-9.

Conclusions Taken together, our results show that in early lupus induction with pristane, HDAC6 gene deletion alters monocyte activation and differentially regulates IFN inducible genes.

800 – Pharmacoepidemiology

801 FACTORS ASSOCIATED WITH SLE FLARES AFTER HCQ TAPER, DISCONTINUATION OR MAINTENANCE IN THE SLICC INCEPTION COHORT: LOWER EDUCATION LINKED WITH HIGHER FLARE RISK

¹Celine C Almeida-Brasil, ²John G Hanly, ³Murray B Urowitz, ⁴Ann E Clarke, ⁵Rosalind Ramsey-Goldman, ⁶Caroline Gordon, ⁷Michelle A Petri, ⁸Ellen M Ginzler, ⁹Daniel J Wallace, ¹⁰Sang-Cheol Bae, ¹¹Juanita Romero-Diaz, ¹²Mary Anne Dooley, ¹³Christine A Peschken, ¹⁴David A Isenberg, ¹⁵Anisur Rahman, ¹⁶Susan Manzi, ¹⁷Soren Jacobsen, ¹⁸Sam Lim, ¹⁹Ronald van Vollenhoven, ²⁰Ola Nived, ²¹Andreas Jonsen, ²²Diane L Kamen, ²³Cynthia Aranow, ²⁴Guillermo Ruiz-Irastorza, ²⁵Jorge Sanchez-Guerrero, ²⁶Dafna D Gladman, ²⁷Paul R Fortin, ²⁸Graciela S Alarcón, ²⁹Joan T Merrill, ³⁰Kenneth C Kalunian, ³¹Manuel Ramos-Casals, ³²Kristjan Steinsson, ³³Asad Zoma, ³⁴Anca Askanase, ³⁵Munther A Khamashta, ³⁶Ian Bruce, ³⁷Murat Inanc, ³⁸Sasha Bernatsky*. ¹Research Institute of the McGill University Health Centre, Canada; ²Queen Elizabeth II Health Sciences Centre, Canada; ³University of Toronto, Canada; ⁴University of Calgary, Canada; ⁵Northwestern University, USA; ⁶Institute of Inflammation and Ageing of the University of Birmingham, UK; ⁷Johns Hopkins University School of Medicine, USA; ⁸SUNY Downstate Medical Center, USA; ⁹Cedars-Sinai Medical Centre, USA; ¹⁰Hanyang University Hospital for Rheumatic Diseases, South Korea; ¹¹Instituto Nacional de Ciencias Médicas y Nutrición, Mexico; ¹²UNC Kidney Centre, USA; ¹³University of Manitoba, Canada; ¹⁴University College London, UK; ¹⁵Allegheny Health Network, USA; ¹⁶Rigshospitalet, Denmark; ¹⁷Emory University School of Medicine, USA; ¹⁸University of Amsterdam, Netherlands; ¹⁹Lund University, Sweden; ²⁰Medical University of South Carolina, USA; ²¹Feinstein Institute for Medical Research, USA; ²²Hospital Universitario Cruces, Spain; ²³Université Laval, Canada; ²⁴University of Alabama at Birmingham, USA; ²⁵Oklahoma Medical Research Foundation, USA; ²⁶UC San Diego School of Medicine, USA; ²⁷Universitat de Barcelona, Spain; ²⁸Landspítali University Hospital, Iceland; ²⁹Hairmyres Hospital, UK; ³⁰Columbia University Medical Centre, USA; ³¹St Thomas' Hospital, UK; ³²University of Manchester, UK; ³³Istanbul University, Turkey

10.1136/lupus-2021-lupus21century.38

Background Hydroxychloroquine (HCQ) is a cornerstone treatment of systemic lupus erythematosus (SLE). We compared time to flare in SLE patients discontinuing/reducing HCQ versus those maintaining their dose, and identified factors associated with time to flare.

Methods We analyzed prospective data from the Systemic Lupus International Collaborating Clinics (SLICC) cohort, which includes SLE patients from 33 sites in Europe, Asia, and North America, enrolled within 15 months of diagnosis and followed annually (1999-2019). We identified patients with HCQ reduction/discontinuation, regardless of disease activity. We evaluated person-time that patients contributed on their initial dose ('maintenance'), comparing this to person-time contributed after a first dose reduction, and person-time after a first HCQ discontinuation. We estimated time to first flare, defined as either subsequent need for therapy augmentation (steroids or other immunomodulators), increase of ≥ 4 points in the SLE Disease Activity Index-2000 (SLEDAI-2K) or hospitalization for SLE. We estimated crude flare rates for each sub-cohort and hazard ratios and 95% confidence intervals (CIs) for various demographic and clinical factors potentially associated with flare risk in the reduction and discontinuation sub-cohorts, as well as comparator maintenance sub-cohorts (matched for time on HCQ to the reduction and discontinuation sub-cohorts).

Results We studied 1460 SLE patients (90% women, 52% Caucasian) on HCQ. Of these, 592 subsequently reduced HCQ at any point, while 407 discontinued HCQ at any point. The crude flare rate for the HCQ reduction sub-cohort was 42.3 per 100 person-years (95% CI 38.6, 46.4), versus 35.6 (95% CI 32.4, 39.1) in the matched maintenance sub-cohort. In the discontinuation sub-cohort, the crude flare rate